Feedback
Settings

Settings

Goto Application

1,843,604 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 184,361
1.WO/2025/141142A NOVEL METHOD FOR RECOVERING LIMONOID COMPOUNDS
WO - 03.07.2025
Int.Class C12P 17/18
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
17Preparation of heterocyclic carbon compounds with only O, N, S, Se, or Te as ring hetero atoms
18containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
 Appl.No PCT/EP2024/088540 Applicant DICOT PHARMA AB Inventor SLAZAK, Blazej
The present invention relates to a novel method for obtaining the limonoid compounds of Formula IIa or IIb, and/or one or more esters and/or derivatives thereof, by culturing plant cells in a cell culture and recovering said compounds from said cells and/or cell culture. In one embodiment of the method the plant cells are obtained or originate from an explant/s of the corresponding plant. The present invention also relates to cell products of the method and the use of said products and compounds.
2.WO/2025/141187T CELLS EXPRESSING ANTI-BCMA/ANTI-CD3 BISPECIFIC ANTIBODIES AND USES THEREOF
WO - 03.07.2025
Int.Class A61K 40/11
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
40Cellular immunotherapy
10characterised by the cell type used
11T-cells, e.g. tumour infiltrating lymphocytes or regulatory T cells; Lymphokine-activated killer cells
 Appl.No PCT/EP2024/088624 Applicant FUNDACIÓN PARA LA INVESTIGACIÓN BIOMÉDICA DEL HOSPITAL UNIVERSITARIO 12 DE OCTUBRE Inventor ÁLVAREZ VALLINA, Luis Manuel
The present invention relates to T cells expressing bispecific antibodies for BCMA and CD3 and uses thereof in the treatment of cancer, in particular cancers which overexpress BCMA antigen.
3.WO/2025/142552OIL-IN-WATER EMULSION COMPOSITION
WO - 03.07.2025
Int.Class A61K 8/368
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
8Cosmetics or similar toiletry preparations
18characterised by the composition
30containing organic compounds
33containing oxygen
36Carboxylic acids; Salts or anhydrides thereof
368with carboxyl groups directly bound to carbon atoms of aromatic rings
 Appl.No PCT/JP2024/044177 Applicant SHISEIDO COMPANY, LTD. Inventor SHISHIDO, Sairi
This oil-in-water emulsion composition contains: (A) an alkoxysalicylic acid represented by general formula (1) or a salt thereof; (B) at least one selected from the group consisting of polyoxyethylene dialkyl esters and polyoxyethylene dialkyl ethers represented by general formula (2); (C) at least one selected from the group consisting of polyoxyethylene alkyl esters and polyoxyethylene alkyl ethers represented by general formula (3); (D) agar; and (E) (i) a carbomer and an alkali agent, (ii) sodium carbomer, or (iii) a carbomer and at least one selected from the group consisting of succinoglycan, xanthan gum, cellulose gum, (acrylic acid/2-(perfluorohexyl) ethyl acrylate) crosspolymers, and (acrylic acid/lauryl methacrylate/isodecyl methacrylate) crosspolymers. The content of the (A) alkoxysalicylic acid represented by general formula (1) or a salt thereof is greater than 1 mass%.
4.WO/2025/143077METHOD FOR PRODUCING PEPTIDE COMPOUND USING STAND-ALONE-TYPE CONDENSING AGENT
WO - 03.07.2025
Int.Class C07K 1/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
1General processes for the preparation of peptides
10using coupling agents
 Appl.No PCT/JP2024/046061 Applicant CHUGAI SEIYAKU KABUSHIKI KAISHA Inventor KOMIYA Shio
Provided is a method for producing a peptide compound or a salt thereof, the method comprising a step (a linking step) in which an amino group of a first amino acid or peptide and a carboxy group of a second amino acid or peptide are linked through an amide bond, wherein in the linking step, a stand-alone-type condensing agent and at least one additive are used, and the additive is at least one selected from the group consisting of HOPO, HOAt, HOOBt, HOCt, PfpOH, Oxyma, Oxyma-B, N-HOSu, and K-Oxyma.
5.WO/2025/143152THIAZOLYL-PYRAZOLO[1,5-A]PYRIDINE COMPOUND AND USE THEREOF AS MYLK4 INHIBITOR
WO - 03.07.2025
Int.Class C07D 471/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
 Appl.No PCT/JP2024/046238 Applicant ZENYAKU KOGYO CO., LTD. Inventor SAITOH Kenichi
The present invention provides a novel compound that inhibits MYLK4 activity, and a pharmaceutical use thereof.　Provided are a compound of formula (I) (wherein R1 to R5 are each independently hydrogen or a C1-3 chained aliphatic hydrocarbon, and R6 is an optionally substituted 5- to 10-membered aromatic hydrocarbon, an optionally substituted 5- to 10-membered heterocycle having 1 to 5 heteroatoms each independently selected from nitrogen, oxygen, and sulfur as a ring atom(s), or a fused ring in which any of the aromatic hydrocarbon and the heterocycle is fused with an optionally substituted 4- to 10-membered heterocyclyl having 1 to 3 heteroatoms each independently selected from nitrogen, oxygen, and sulfur as a ring atom(s)) or a pharmaceutically acceptable derivative thereof, and a pharmaceutical use of the compound or the derivative.
6.WO/2025/145057TRANSIENT RECEPTOR POTENTIAL MELASTATIN 2 (TRPM2) MODULATORS AND USES THEREOF
WO - 03.07.2025
Int.Class A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
 Appl.No PCT/US2024/062121 Applicant UNIVERSITY OF CONNECTICUT Inventor YUE, Lixia
The present invention relates to modulators that inhibit the interaction between protein kinase C y (PKCy) and transient receptor potential melastatin 2 (TRPM2), including peptides, polypeptides, and small molecules, and their use in treatment of neurological and cardiovascular diseases.
7.WO/2025/145087CONSTRUCTS TARGETING MSLN PEPTIDE/MHC COMPLEXES AND USES THEREOF
WO - 03.07.2025
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
 Appl.No PCT/US2024/062156 Applicant EUREKA THERAPEUTICS, INC. Inventor CUI, Ziyou
The present application provides constructs comprising an antibody moiety that specifically binds to MHC molecules complexed with mesothelin peptides. Also provided are methods of making and using these constructs, and uses thereof, including treating and diagnosing diseases.
8.WO/2025/145207COMBINATION THERAPY OF KRAS INHIBITOR AND TREG-DEPLETING AGENT
WO - 03.07.2025
Int.Class G01N 33/50
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
 Appl.No PCT/US2024/062349 Applicant BRISTOL-MYERS SQUIBB COMPANY Inventor DOWNWARD, David, Julian, Harry
In some aspects, the present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising administering a KRAS inhibitor and a regulatory T cell (Treg)-depleting agent to the subject. In some aspects, the present disclosure is further directed to methods of reducing the number of Treg cells (Tregs) in a tumor environment (TME) in a subject who receives a therapy with a KRAS inhibitor comprising administering a Treg-depleting agent to the subject. In some aspects, the present disclosure is further directed to methods of treating a tumor in a subject who is identified as having an increased number of Tregs in a TME, or as having a spatial cellular community comprising Tregs in a TME.
9.WO/2025/144772IMPROVED COMPOSITIONS AND METHODS FOR FECAL MICROBIOTA TRANSPLANTATION AND MICROBIOTA TRANSPLANT THERAPIES
WO - 03.07.2025
Int.Class A61K 35/741
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
74Bacteria
741Probiotics
 Appl.No PCT/US2024/061651 Applicant REGENTS OF THE UNIVERSITY OF MINNESOTA Inventor SADOWSKY, Michael, J.
The present disclosure provides freeze-dried compositions that include an extract of human feces and a flavoring agent, where the compositions, upon reconstitution with a liquid, have no objectionable odor and has no objectionable taste. Also provided are methods for making and using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease. In some embodiments, the subject can be an individual with reduced ability to swallow, such as pill dysphagia, or an individual refractory to administration of a liquid having an objectionable odor or objectionable taste.
10.WO/2025/144847SHORT CHAIN FATTY ACID COMPOUNDS AND USES THEREOF
WO - 03.07.2025
Int.Class A61K 31/19
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
 Appl.No PCT/US2024/061844 Applicant TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION Inventor ARZUMANYAN, Alla
The present disclosure describes methods comprising obtaining a level of a biomarker in a subject and based on the level of the biomarker in the subject, continuing a short chain fatty acid therapy. The disclosed methods can comprise administering a composition comprising at least one short chain fatty acid. The disclosed methods can be used to treat an inflammatory condition, a skin disorder, or an autoimmune disorder.
# -